Our Science AT-527 COVID-19 About Atea Investors Careers Contact AT-527 A leader in the discovery of oral direct-acting antiviral therapies. Atea’s most advanced antiviral drug candidate, AT-527, is being evaluated in MORNINGSKY, a global multi-center Phase 3 clinical trial for the treatment of patients with mild or moderate COVID-19 in an outpatient setting. As an orally-administered direct-acting antiviral, AT-527 is designed to arrest the progression of COVID-19 by inhibiting replication of the SARS CoV-2 virus. Complementary medical intervention to vaccination similar to the influenza paradigm (Tamiflu®) Significant advantages vs antibodies: convenient for patients and healthcare workers global reach manufacture scale-up cost Highly-conserved target has potential to enable antiviral activity in the presence of multiple variants Antiviral activity against potential future coronaviruses beyond SARS-CoV-2 anticipated November 22nd, 2021 Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will participate in a virtual fireside chat at the 4th Annual READ MORE November 16th, 2021 Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche Atea to lead global clinical trial development of AT-527 and regain ex-US commercial rights BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the strategic collaboration pursuant to which it READ MORE November 11th, 2021 Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results Phase 3 MORNINGSKY Protocol Amendment to Include New Primary Endpoint, Refined Patient Population and Increased Dose, with Plan to Accelerate Completion of Enrollment Infectious Virus Data Demonstrate AT-527’s Rapid and Potent Antiviral Activity Against COVID-19 in Phase 2 MOONSONG Overall Patient READ MORE ALL NEWS & PRESS RELEASES Atea is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatment. Atea Pharmaceuticals, Inc. 125 Summer Street Boston, MA 02110 (857) 284-8891 Copyright © 2020 By Atea Pharmaceuticals. All Rights Reserved. Privacy Policy | Terms of Use